BioXcel announces FDA acceptance of IND for lead neuroscience candidate, BXCL501
BioXcel announced the FDA has accepted its IND application for lead neuroscience candidate, BXCL501. BTI plans to evaluate BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex) in a first-in-human pharmacokinetic (bioavailability) and safety study in healthy volunteers. December 12, 2018